NRx Pharmaceuticals (NRXP) Stock Overview
A clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
NRXP Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
NRx Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.27 |
| 52 Week High | US$6.01 |
| 52 Week Low | US$1.10 |
| Beta | 1.74 |
| 1 Month Change | 25.77% |
| 3 Month Change | -3.25% |
| 1 Year Change | 112.34% |
| 3 Year Change | -58.08% |
| 5 Year Change | -96.97% |
| Change since IPO | -96.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRXP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.8% | 10.3% | 1.2% |
| 1Y | 112.3% | -2.2% | 17.9% |
Return vs Industry: NRXP exceeded the US Pharmaceuticals industry which returned -3.4% over the past year.
Return vs Market: NRXP exceeded the US Market which returned 18.7% over the past year.
Price Volatility
| NRXP volatility | |
|---|---|
| NRXP Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NRXP has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NRXP's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Jonathan Javitt | www.nrxpharma.com |
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital.
NRx Pharmaceuticals, Inc. Fundamentals Summary
| NRXP fundamental statistics | |
|---|---|
| Market cap | US$79.15m |
| Earnings (TTM) | -US$33.79m |
| Revenue (TTM) | n/a |
Is NRXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRXP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$33.79m |
| Earnings | -US$33.79m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.42 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -27.7% |
How did NRXP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 13:56 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NRx Pharmaceuticals, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Thomas Shrader | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |